Insider Selling: IDEXX Laboratories (NASDAQ:IDXX) Director Sells $1,172,172.24 in Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director Lawrence Kingsley sold 2,203 shares of the stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the transaction, the director owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. The trade was a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

IDEXX Laboratories Trading Down 0.4%

NASDAQ IDXX opened at $504.70 on Friday. The stock has a market capitalization of $39.76 billion, a price-to-earnings ratio of 35.49, a PEG ratio of 2.70 and a beta of 1.54. The stock’s 50 day moving average price is $555.59 and its two-hundred day moving average price is $566.45. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. IDEXX Laboratories, Inc. has a 52 week low of $500.61 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. The firm had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The business’s revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of IDXX. Empowered Funds LLC grew its holdings in IDEXX Laboratories by 6.6% during the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock worth $646,000 after purchasing an additional 95 shares during the period. Sivia Capital Partners LLC bought a new stake in IDEXX Laboratories in the second quarter valued at approximately $265,000. Jump Financial LLC raised its stake in IDEXX Laboratories by 1,006.4% in the second quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock valued at $2,967,000 after buying an additional 5,032 shares during the period. Cary Street Partners Financial LLC acquired a new stake in shares of IDEXX Laboratories in the second quarter valued at approximately $164,000. Finally, Sei Investments Co. lifted its position in shares of IDEXX Laboratories by 218.7% in the second quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock valued at $64,678,000 after buying an additional 82,755 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on IDXX. Barclays decreased their target price on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. UBS Group increased their price objective on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Citigroup lifted their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, August 27th. Finally, Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $747.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops and provides diagnostic, information technology and veterinary practice-management products and services. The company primarily serves the companion animal, livestock and poultry, and water testing markets, helping customers detect, monitor and manage disease.

Its companion animal business includes in-house laboratory analyzers and consumables, reference laboratory services, diagnostic tests, veterinary software, digital imaging and related practice-management solutions.